Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen 4Q Results

Revenue from product launches offset decline in multiple sclerosis product revenue, down 8% to $1.1 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen

4Q Revenues: $2.5 billion (+3%)

4Q Earnings: $267 million (+7%)

FY Revenues: $9.7 billion (-2%)

FY Earnings: $1.6 billion (+41%)

Comments: Revenue from product launches offset decline in multiple sclerosis product revenue, down 8% to $1.1 billion. Tecfidera sales were $227.8 million, down 7% and Vumerity sales were $176.6 million, up 13%. Avonex sales were $170 million, down 17%. Tysabri sales were $415.4 million, down 11%.

Rare Disease revenue was $535.3 million in the quarter, up 13%. Spinraza sales were $421.4 million, up 2%. Global Skyclarys revenue was $102.2 million in the quarter, compared to $56 million 4Q23, nearly doubling the number of patients on therapy globally; U.S. Skyclarys revenue of approximately $71 million was impacted by inventory and Medicare discount dynamics. Skyclarys was obtained as part of the acquisition of Reata in September 2023. 

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%.

LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S. in-market sales of approximately $50 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics